These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11153825)

  • 21. Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation.
    Minami T; Isomoto S; Nakao K; Komiya N; Fukae S; Centurion OA; Yano K
    Pacing Clin Electrophysiol; 2004 Feb; 27(2):212-7. PubMed ID: 14764172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Nifekalant hydrochloride effective against perioperative ventricular tachycardia in patients with impaired left ventricular function].
    Murakami T; Makino Y; Kato H
    Kyobu Geka; 2007 Jun; 60(6):469-73. PubMed ID: 17564063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiarrhythmic efficacy of a new class III agent, UK-68,798, during chronic myocardial infarction: evaluation using three-dimensional mapping.
    Zuanetti G; Corr PB
    J Pharmacol Exp Ther; 1991 Jan; 256(1):325-34. PubMed ID: 1988663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action.
    Kushida S; Ogura T; Komuro I; Nakaya H
    Eur J Pharmacol; 2002 Dec; 457(1):19-27. PubMed ID: 12460639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Verapamil responsive incessant ventricular tachycardia resulting in severe ventricular dysfunction in a young child: successful management with oral verapamil.
    Ma JS; Kim BJ; Cho JG
    Heart; 1997 Mar; 77(3):286-7. PubMed ID: 9093053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest.
    Ji XF; Li CS; Wang S; Yang L; Cong LH
    Resuscitation; 2010 Aug; 81(8):1031-6. PubMed ID: 20627529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug Therapy for Shock-Resistant Ventricular Fibrillation: Comparison of Nifekalant and Amiodarone].
    Harayama N; Nihei S; Nagata K; Aibara K; Kamochi M; Sata T
    J UOEH; 2016 Mar; 38(1):35-46. PubMed ID: 26972943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
    Stambler BS; Gottlieb SS; Singh BN; Ramanathan KB; Ogilby JD; Ellenbogen KA
    J Am Coll Cardiol; 1995 Dec; 26(7):1679-84. PubMed ID: 7594103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracoronary verapamil rapidly terminates reperfusion tachyarrhythmias in acute myocardial infarction.
    Kato M; Dote K; Sasaki S; Takemoto H; Habara S; Hasegawa D
    Chest; 2004 Sep; 126(3):702-8. PubMed ID: 15364745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig.
    Tuininga YS; De Langen CD; Crijns HJ; Wiesfeld AC; Mook PH; Bel KJ; Lie KI
    Pacing Clin Electrophysiol; 1996 May; 19(5):802-10. PubMed ID: 8734747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological therapy in coronary heart disease: prevention of life-threatening ventricular tachyarrhythmias and sudden cardiac death.
    Kochs M; Eggeling T; Hombach V
    Eur Heart J; 1993 Sep; 14 Suppl E():107-19. PubMed ID: 8223747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias.
    Gautier P; Serre M; Cosnier-Pucheu S; Djandjighian L; Roccon A; Herbert JM; Nisato D
    J Cardiovasc Pharmacol; 2005 Feb; 45(2):125-35. PubMed ID: 15654261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias.
    Pantazopoulos IN; Troupis GT; Pantazopoulos CN; Xanthos TT
    World J Cardiol; 2011 Jun; 3(6):169-76. PubMed ID: 21772943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models.
    Satoh Y; Sugiyama A; Takahara A; Chiba K; Hashimoto K
    J Cardiovasc Pharmacol; 2004 May; 43(5):715-23. PubMed ID: 15071360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic management of atrial fibrillation: current therapeutic strategies.
    Lévy S
    Am Heart J; 2001 Feb; 141(2 Suppl):S15-21. PubMed ID: 11174354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Strategy for cardiac arrhythmias in acute coronary syndrome].
    Sugi K
    Nihon Rinsho; 2006 Apr; 64(4):729-33. PubMed ID: 16613191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ventricular tachycardia associated with acute myocardial infarction--features, therapeutic effect and prognosis.
    Hayakawa H; Katoh T; Nejima J; Iida K; Tanaka K; Takano T
    Jpn Circ J; 1985 Mar; 49(3):362-9. PubMed ID: 3981794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation.
    Wang J; Hua W; Zhu J; Yang YM; Wang FZ; Pu JL; Chen KP; Zhang S
    Chin Med J (Engl); 2010 Aug; 123(15):2028-33. PubMed ID: 20819537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic drug prescription in patients after myocardial infarction in the last decade. Experience of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI).
    Avanzini F; Latini R; Maggioni A; Colombo F; Santoro E; Franzosi MG; Tognoni G
    Arch Intern Med; 1995 May; 155(10):1041-5. PubMed ID: 7748046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E4031 in a canine model of previous myocardial infarction.
    Lynch JJ; Heaney LA; Wallace AA; Gehret JR; Selnick HG; Stein RB
    J Cardiovasc Pharmacol; 1990 May; 15(5):764-75. PubMed ID: 1692937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.